Filing Flows › Emmaus Life Sciences (EMMA) › Q2 2026
Emmaus Life Sciences (EMMA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Emmaus Life Sciences (EMMA) reported revenue of $6.3M for the second quarter 2026 (Q2 2026), +124% from a year earlier and +219% from the quarter before. Operating margin was 60.0%, net earnings $1.3M (21.2% of revenue).
Emmaus Life Sciences, Q2 2026: revenue $6.3M (+124% year over year), operating margin 60.0%, net earnings $1.3M, operating cash flow $1.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.3M | +219% | +124% |
| Gross profit | $6.0M | +229% | +124% |
| Operating profit | $3.8M | — | — |
| Net earnings | $1.3M | — | — |
| Operating cash flow | $1.7M | — | — |
What changed
Revenue was $6.3M in Q2 2026, up 124% year over year and up 219% from the previous quarter. Endari US was the largest line at 95% of revenue. Endari US added $3.7M year over year (up 158%), 105% of the total change. Endari International declined 38%.
Gross margin was 94.6%, down 0.1 points from Q2 2025. Operating profit was $3.8M, a 60.0% margin (up 73.1 points year over year). Operating expenses fell 28% while revenue rose 124%. The fastest-growing cost line was Research & development (+107%). Net earnings were $1.3M. The effective tax rate was -0.1%.
Operating cash flow was $1.7M, 126% of net earnings. Non-cash charges added back $14K of depreciation. Working capital and other items added $340K.
Questions
What was Emmaus Life Sciences' revenue in the second quarter 2026?
Emmaus Life Sciences (EMMA) reported revenue of $6.3M for the second quarter 2026 (Q2 2026), +124% from a year earlier and +219% from the quarter before.
Was Emmaus Life Sciences profitable in the second quarter 2026?
Operating profit was $3.8M (60.0% of revenue) and net earnings $1.3M.